Loading...

Current Issue


02 November 2019, Volume 1 Issue 1   
Announcing the launch of a new journal: Asian Toxicology Research
Xing-Zhi Wu
8Asian Toxicology Research. 2019, 1 (1): 1-1.   https://doi.org/10.12032/atr2019-1101-001
Abstract ( 29 )     PDF (151KB) ( 10 )  
Asian Toxicology Research has been planned as an international open access, peer reviewed journal dedicated
to environment and research results of clinical toxicology of pharmaceuticals, safety evaluation of
health foods, cosmetics, pharmaceuticals, toxicity assessment of new chemicals, new technologies and
methods of toxicology experimental research, and new toxicology theories, with a special focus within
China and other Asian countries. Among them, the Asia Focus column is the feature of this journal,
which focuses on the research results, guideline interpretation and health policy in the fields of Ai,
aroma, tea, traditional Chinese medicine, Chinese food, air pollution, water pollution, pesticides,
genetically modified and so on. Based in Asia and facing the world, this journal aims to reflect
the new progress, achievements and technologies of toxicology research in Asia and even in the
world, and to promote domestic and international exchanges in this field. We welcome and encourage
the submission of high-quality, original papers, and look forward to publishing more insightful research
articles in the journal.
Therapeutic Safety and Efficacy of Erenumab for Treatment in Migraine Patients: A Systematic Review and Meta-analysis
Peng Chen, Fuchao Chen, Jiexin Lei, Benhong Zhou
8Asian Toxicology Research. 2019, 1 (1): 2-17.   https://doi.org/10.12032/atr2019-1101-002
Abstract ( 36 )     PDF (608KB) ( 16 )  
Background: Calcitonin gene-related peptide (CGRP) plays an important role in migraine
pathophysiology. Erenumab, a human monoclonal antibody (mAb) that inhibits the CGRP appear more
promising for migraine because of effective and well tolerated profiles. The purpose of this study is to
perform a meta-analysis to evaluate the therapeutic safety and efficacy of erenumab for treatment in
migraine patients.
Methods: We searched multiple sources included PubMed, Embase, Cochrane library, and CNKI data
based on collected the double-blinded randomized clinical trials comparing erenumab to placebo. After
data extraction and quality assessment of the included RCTs, the RevMan 5.3 software was applied for
meta-analysis of reduction of monthly migraine days (MMD), the proportion of patients reaching 50%
reduction in MMD, the reduction of monthly acute migraine-specific medication treatment days (MSMD),
and 50% responder rate. As for the safety, total adverse events and the main adverse events were assessed.
Results: We included data from 5 randomized clinical trials,with a total of 3349 participants. We found
significant reduction of MMD and MSMD in erenumab vs. placebo (WMD= -1.31, 95%CI -1.78 to -0.83,
P < 0.00001; WMD= -1.24, 95% CI -1.63 to -0.83, P < 0.00001). The proportion of patients reaching
50% reduction in MMD (OR= 2.01, 95% CI 1.78 to 2.49, P < 0.00001) and 50% responder rate (OR=
1.70, 95%CI: 1.23 to 2.35, P = 0.001) were significantly increased compared with placebo. There was no
significant difference in total adverse events (OR=1.02, 95%CI: 0.84-1.24), and the main adverse events
including upper respiratory tract infection (OR=1.14, 95%CI 0.84-1.56), nasopharyngitis (OR=0.85,
95%CI 0.66-1.10), migraine (OR=0.82, 95%CI 0.51-1.33), and nausea (OR=0.98, 95%CI 0.63-1.53),
were not obviously changed compared with placebo control, but the results showed significant increase of
injection-site pain in erenumab vs placebo (OR=2.48, 95%CI 1.45-2.46).
Conclusion: This meta-analysis suggests that erenumab is effective in anti-migraine therapy with few
adverse, and further high-quality studies should be conducted to confirm our findings.
Effect and safety of Kanglaite injection combined with chemotherapy in the treatment of advanced colorectal cancer: systematic review and meta-analysis
Jinlin Wu, Zhu Yang, Fengxi Long, Bing Yang, Xun Liu, Xianman Wei, Dongxin Tang
8Asian Toxicology Research. 2019, 1 (1): 18-28.   https://doi.org/10.12032/atr2019-1101-003
Abstract ( 31 )     PDF (594KB) ( 14 )  
Objective: To evaluate the clinical efficacy and safety of Kanglaite injection combined with
chemotherapy and chemotherapy alone in the treatment of advanced colorectal cancer.
Methods: PubMed, Cochrane library, CNKI, VIP, Wanfang database were systematically searched by
inputting keywords to explore the efficacy of Kanglaite injection combined with chemotherapy in the
treatment of advanced colorectal cancer. A random-effects model was selected to evaluate the treatment
outcomes. The screening of literature, the extraction of data and the assessment of methodology were
independently undertaken by two reviewers. Meta analysis was performed using Revman5.3 software and
stata15.0 software.
Results: A total of 12 RCTs were included, with 792 cases. Compared with chemotherapy alone, Metaanalysis
suggested that Kanglaite injection combined with chemotherapy can improve clinical efficiency
(RR=1.45, 95% CI: 1.21-1.74, P < 0.0001) and improve patients' quality of life (RR = 1.55, 95% CI:
1.32-1.82, P < 0.00001), improve the patient's immune function (CD3+ cells: SWD=1.42, 95% CI:
1.11-1.73; CD4+/CD8+ cell ratio: SWD=0.95, 95% CI: 0.66- 1.25; NK cell activity: SWD = 3.24, 95%
CI: 2.81-3.66, P < 0.00001); Leukopenia rate (RR=0.63, 95% CI: 0.54-0.74, P < 0.0001), incidence of
gastrointestinal adverse reactions (RR=0.56, 95% CI: 0.48-0.66, P < 0.00001), incidence of peripheral
neurotoxicity (RR=0.79, 95% CI: 0.65-0.96, P = 0.02) were lower than the chemotherapy alone group,
the difference was statistically significant. In improving the hand-foot syndrome and oral mucositis after
chemotherapy, there was some difference between the Kanglaite injection combined with chemotherapy
group and the chemotherapy alone group, but the difference was not significant. Puber bias detection and
sensitivity analysis were performed with clinically effective relative risk (RR) as indicators. The results
suggested that the publication bias was not obvious. The results of this study are stable.
Conclusion: Compared with chemotherapy alone group in the treatment of advanced colorectal cancer,
Kanglaite injection combined with chemotherapy can improve the effective rate, quality of life, immune
function of patients and reduce the incidence of leukopenia after chemotherapy, gastrointestinal adverse
reactions and peripheral neurotoxicity.
Random Forest Analysis the Influencing Factors on Adverse Drug Reactions of Qingkailing Injection
Meng-Meng Ji, Hong-Li Wu, Wei Yang, Jun Liu, Ya-Nan Yu, Zhong Wang, Zhi-Wei Jing
8Asian Toxicology Research. 2019, 1 (1): 29-36.   https://doi.org/10.12032/atr2019-1101-004
Abstract ( 22 )     PDF (311KB) ( 15 )  
Objective: To investigate the influencing factors of adverse drug reaction (ADR) in Qingkailing injection.
Methods: Based on the hospitals centralized monitoring data of multicenter and prospective, the patients
who used Qingkailing injection from January 2013 to March 2016 were monitored in 48 medical
institutions in China. The nesting case-control study was used and the random forest was used for
analysis. The main contents of the analysis are as follows: past history, past allergy history and ADR
history, clinical diagnosis, dosage, interval drug, solvent type, combined drug use, etc.
Results: A total of 30842 cases with Qingkailing injection were included, with 92 cases of adverse
reactions and the incidence of adverse reactions was 3‰. According to the nested case-control study
design, the influencing factors of 92 patients with ADR and 276 non-drug-related adverse reactions were
displayed on the basis of statistical description (significance level P ≤ 0.2 and clinical information) using
Random forest analysis shows that the factors affecting the ADR of the Qingkailing injection according
to the MeandecaseGini are from high to low in the first 15 positions: Vitamin supplements, tumors,
gastrointestinal diseases, traditional Chinese medicine, previous allergic history, cerebral insufficiency,
rash, urinary tract infection, vascular and lymphovascular diseases, pioglitazone, metabolic and endocrine
system drugs, past ADR history, respiratory and mediastinal diseases, dioxpromazide, pneumonia.
Conclusion: The incidence of adverse reactions in Qingkailing injection hospital is 3%. The factors
closely related to the occurrence of ADR are previous tumors, gastrointestinal diseases, history of adverse
reactions of rash, urinary tract infection, insufficient cerebral blood supply, respiratory system and other
diseases, pioglitazone and other combined drugs.
Effects and safety of Chinese herbals containing Houttuynia cordata Thunb in the treatment of lung cancer : a systematic review
Li-Ting Yu, Wei-Xiu Fan, Li-Ping Yang, Ai-Xin Shi
8Asian Toxicology Research. 2019, 1 (1): 37-50.   https://doi.org/10.12032/atr2019-1101-005
Abstract ( 23 )     PDF (330KB) ( 15 )  
Objective: This study systematically evaluates the efficacy and safety of Houttuynia cordata in the
treatment of lung cancer in order to provide clinical data support for better application of Houttuynia
cordata.
Methods: PubMed, EMbase, Web of Science, ScienceDirect, Scopus, CNKI, WanFang Data, VIP and
SinoMed were used to retrieve clinical observations and clinical controlled studies of Houttuynia cordata
in the treatment of lung cancer. The retrieval time ranges from database building to January 2019. Two
researchers independently screened literature, extracted data and conducted computational analysis.
Result: In the clinical observational study, 12 literatures of pure Chinese medicine treatment (1473
patients) and 4 literatures of combined Chinese and Western medicine treatment (193 patients) were
compared. The total effective rate and total stable rate of combined Chinese and Western medicine
treatment for tumour control were better, but the total improvement rate of quality of life of combined
Chinese and Western medicine treatment was lower than that of pure Chinese medicine, and the incidence
of adverse reactions such as bone marrow suppression and gastrointestinal tract reaction was also higher
than that of pure Chinese medicine. Chinese medicine
In the clinical control study, 8 articles (567 patients) in the treatment group were treated by Chinese
medicine and 9 articles in the treatment group (530 patients) were treated by combination of Chinese
and Western medicine. Compared with Chinese medicine group, the total effective rate and total stability
rate in the control of tumor size were higher in the combination of Chinese and Western medicine; The
survival rate of 0.5~ 2 years was higher, and the total effective rate of body weight gain was slightly
higher in the combination of Chinese and Western medicine. At the same time, the incidence of side
effects was significantly higher than that of pure Chinese medicine treatment group. In addition, compared
with the control group, the incidence of all side effects in the pure Chinese medicine group was lower.
Compared with the control group, besides "bleeding", "oral reaction" and "skin reaction", the probability
interval of side effects in the treatment group was less than that in the control group, and the degree of
side effects was also less than that in the chemotherapy group.
Conclusion: In the treatment of lung cancer, the use of herbs containing Houttuynia cordata combined
with western medicine or radiotherapy and chemotherapy not only has good curative effect, but also
reduces toxicity and side effects. Therefore, the combination of herbs with western medicine has unique
advantages, which deserves further in-depth research and development.